Complement deficiency diagnosis follows a systematic, pathway-based algorithm that starts with functional screening and ends with targeted protein measurement. The recommended workflow begins with three functional assays—CH50 (classical pathway), AH50 (alternative pathway), and in some protocols a lectin pathway screen (LP). An isolated low result narrows the defect to a specific pathway: low CH50 alone points to classical components (C1q, C1r, C1s, C4, or C2), low AH50 alone implicates alternative pathway factors (Factor B, Factor D, properdin, or regulatory proteins), and low activity across multiple pathways suggests a terminal defect (C3, C5–C9) or systemic consumption. This tiered logic directly guides immunoassay kit design, mandating paired functional lytic assays alongside quantitative single-analyte immunoassays for C3, C4, C1-inhibitor, and regulatory proteins—each built on highly specific antibodies and stable calibrators to differentiate single versus multiple component deficiencies and detect dysfunctional protein variants.
The core diagnostic strategy is a two‑tier cascade: functional screening (CH50/AH50) identifies the affected pathway, and then quantitative immunoassays pinpoint the deficient protein. For kit developers, this means engineering a seamless diagnostic system—from robust lytic reagents that survive transport and storage, to monospecific antibodies and recombinant calibrators that deliver accurate quantification even when the protein is present but non‑functional.
The Tiered Diagnostic Workflow for Complement Deficiencies
Starting with Functional Pathway Screening
The CH50 assay measures the serum dilution needed to lyse 50% of antibody‑sensitized sheep erythrocytes, reflecting the entire classical cascade from C1 through C9.
A low CH50 signals a functional block somewhere in that sequence.
The AH50 assay uses rabbit erythrocytes as an alternative pathway activator.
It includes EGTA to chelate calcium, which blocks the classical pathway while leaving magnesium‑dependent alternative activation intact.
This isolates the alternative pathway’s lytic capacity (Factor B, Factor D, properdin, and regulators like Factor H and Factor I).
A dedicated lectin pathway assay, often based on MBL binding to mannan‑coated plates, screens for mannose‑binding lectin (MBL) and MASP protease deficits.
When all three screens are run in parallel, the pattern immediately directs follow‑up testing.
Interpreting the Pattern: Isolated vs. Combined Deficiencies
Low CH50 with a normal AH50 points exclusively to classical pathway components—C1q, C1r, C1s, C4, or C2.
This is the classic pattern for early complement defects that leave the alternative and terminal pathways intact.
Normal CH50 with a low AH50 indicates a selective alternative pathway problem.
The cause can be a missing factor (Factor B, Factor D, properdin) or a regulatory dysfunction (Factor H, Factor I) that leads to uncontrolled consumption.
Low CH50 and low AH50 signals a defect in the shared terminal pathway (C3, C5, C6, C7, C8, or C9), or severe systemic consumption that depletes multiple components.
A low C4 with a low C3 further suggests immune‑complex‑driven consumption, as in active systemic lupus erythematosus.
A low lectin pathway result alone isolates MBL or MASP‑1/2 deficiencies.
These patients may still have normal CH50 and AH50 because the classical and alternative pathways remain functional.
The Role of Confirmatory Quantitative Immunoassays
Once the functional defect is localized, component‑specific immunoassays measure the actual protein concentration.
Turbidimetry, nephelometry, or sandwich ELISA formats using purified antibodies against C3, C4, C1‑INH, Factor H, and Factor I become the definitive step.
A normal protein level paired with low functional activity reveals a dysfunctional protein variant—a mutation that impairs activity without reducing synthesis.
This is impossible to detect by concentration measurement alone, reinforcing why functional screening must always precede quantification.
In consumption‑driven states like severe lupus, both C3 and C4 are low.
In hereditary angioedema, C1‑INH is quantitatively low (type I) or functionally defective with normal or even elevated antigen levels (type II), making paired functional and antigen tests obligatory.
Translating the Diagnostic Workflow into Immunoassay Kit Design
Designing Functional Screening Kits (CH50/AH50)
Functional kits must deliver standardized, lyophilized activator reagents that retain their sensitivity after reconstitution.
For CH50, this means antibody‑sensitized sheep erythrocytes with consistent hemolytic fragility.
For AH50, rabbit erythrocytes or alternative‑specific liposomes must remain stable without spontaneous lysis.
The buffer formulation is critical.
The AH50 assay’s EGTA‑magnesium buffer must reliably block C1q‑dependent activation without affecting the alternative pathway.
Any drift in calcium‑chelation efficiency will produce false‑positive classical pathway interference.
Developers must also supply normal reference sera with precisely defined lytic activity.
These controls define the “normal” range and let laboratories validate that the kit’s erythrocytes and incubation conditions are performing correctly.
Developing Quantitative Single‑Analyte Immunoassays
High‑purity monospecific antibodies are the backbone of reliable component quantification.
Polyclonal or monoclonal antibodies must be absorbed against cross‑reacting complement fragments to avoid overestimating proteins like C3 (where C3c and C3d can cause interference).
Recombinant antigen calibrators ensure traceability and lot‑to‑lot consistency.
They must be expressed in systems that preserve the native conformation, so the calibrator behaves identically to the endogenous protein in the assay.
The assay platform—be it ELISA, nephelometry, or turbidimetry—must achieve the limit of detection required to distinguish severe deficiency from normal low‑normal levels.
For C1‑INH deficiency, the assay must also recognize the dysfunctional protein in type II HANE, meaning the antibody must bind an epitope present on both functional and non‑functional molecules unless a specific functional‑epitope antibody is used.
Quality Control and Reference Materials
Stable serum‑based controls, lyophilized and value‑assigned for each pathway activity and protein concentration, are indispensable.
They enable laboratories to monitor day‑to‑day variation and verify that the kit’s lytic or immunochemical detection system remains within specification.
Developers must also provide calibrators normalized against international standards (such as WHO reference preparations) so results are comparable across manufacturers.
Without this harmonization, a “low” C4 on one platform may be “borderline” on another, undermining the diagnostic algorithm.
Understanding the Trade‑offs and Pitfalls in Assay Design
Functional vs. Quantitative: Why You Need Both
A functional screen cannot name the missing protein, but it reveals pathway integrity—the most clinically relevant parameter for suspecting an immunodeficiency.
Conversely, a quantitative assay alone can miss a dysfunctional protein that is present at normal levels, falsely reassuring the clinician.
The diagnostic algorithm therefore demands a paired approach.
Any kit that pushes only functional or only quantitative testing risks incomplete diagnoses.
Challenges with Functional Assay Standardization
CH50 and AH50 assays are exquisitely sensitive to serum handling.
Complement proteins are heat‑labile; serum must be separated at 4 °C and stored at −70 °C, because even a few freeze‑thaw cycles can degrade activity.
Manufacturers can mitigate this by supplying freeze‑dried control sera and by incorporating stabilising additives (sucrose, trehalose) in lytic reagents.
Nevertheless, field performance will always be influenced by pre‑analytical variables, so a well‑designed kit must include robust lot‑specific normal ranges that account for typical collection variability.
Antibody Specificity and Calibration Hurdles
Complement activation generates cleavage fragments that share epitopes with the parent protein.
Antibodies that cross‑react with C3c or C4d will over‑estimate the intact protein, masking consumption.
Designers must epitope‑map antibodies to domains that are lost or hidden upon activation, or use fragment‑specific capture/detection pairs.
Calibrator stability is another common pitfall.
Recombinant antigens can aggregate or degrade in solution if formulation excipients are not carefully optimised, leading to drifting standard curves and misclassification of patient samples.
Making the Right Choice for Your Diagnostic Panel
After mapping the clinical workflow to assay design requirements, you can tailor your product offering to specific diagnostic goals.
- If your primary focus is routine screening for autoimmune diseases like SLE: Design a streamlined panel with CH50, C3, and C4. A normal CH50 with low C3/C4 suggests consumption, while a persistently low CH50 with normal C3/C4 may prompt referral for full pathway investigation.
- If your primary focus is comprehensive complement deficiency profiling: Assemble a full‑system menu: CH50, AH50, LP screen, plus quantitative assays for C1q, C1‑INH, C3, C4, Factor B, Factor H, Factor I, and optionally C5–C9. Include both antigenic and functional assays for C1‑INH to catch type II HANE.
- If your primary focus is point‑of‑care or low‑resource testing: Prioritize easy‑to‑interpret lytic assays with lyophilized reagents and visual readouts. Pair them with rapid, instrument‑free quantitative lateral‑flow immunoassays for the most clinically actionable markers—C3, C4, and C1‑INH.
By mirroring the clinical diagnostic logic in your kit design, you supply laboratories with a coherent system that turns functional screening results into actionable quantitative insights—closing the loop between suspicion and a definitive molecular diagnosis.
Summary Table:
| Diagnostic Stage | Assays & Targets | Clinical Function | Immunoassay Kit Design Requirements |
|---|---|---|---|
| Tier 1: Functional Screening | CH50 (Classical), AH50 (Alternative), LP (Lectin) | Assesses total pathway lytic activity; identifies functional blockades. | Lyophilized activator erythrocytes, precise EGTA-Mg buffers, standardized reference sera. |
| Tier 2: Quantitative Confirmation | Single-analyte immunoassays (C3, C4, C1-INH, Factor H/I) | Measures specific protein levels; identifies dysfunctional protein variants. | Monospecific antibodies with low fragment cross-reactivity, recombinant native-state calibrators. |
| Quality & Standardization | WHO-aligned reference materials, controls | Ensures lot-to-lot consistency and inter-laboratory comparability. | Freeze-dried value-assigned control sera, stabilized excipient formulations. |
Accelerate your complement assay development with CamelBio. We provide diagnostic manufacturers, labs, and research institutes with one-stop access to high-quality IVD raw materials, technical services, and expert consulting—covering every stage from concept to clinic. Whether you need monospecific antibodies, recombinant calibrators, or customized assay optimization for CH50, AH50, C3, and C4 panels, our experts are here to support your pipeline. Contact us today to start your project!